Erlotinib (Tarceva) for non small cell lung cancer - advanced or metastatic, maintenance after first-line therapy and second line (in combination with bevacizumab): horizon scanning technology briefing

Category Structured summary of systematic reviews
JournalHTA Database
Year 2009
RECORD STATUS: None CITATION: National Horizon Scanning Centre. Erlotinib (Tarceva) for non small cell lung cancer - advanced or metastatic, maintenance after first-line therapy and second line (in combination with bevacizumab): horizon scanning technology briefing . National Horizon Scanning Centre (NHSC).
Epistemonikos ID: 0f1093be01026019aad44bad2528aa367beb042d
First added on: Feb 05, 2015